Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer

Affiliations

¹ The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, United Kingdom.
² Guy's and St. Thomas NHS Foundation Trust, United Kingdom.
³ The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, United Kingdom. Electronic address: Johann.De-Bono@icr.ac.uk.

Comment

David Lorente et al. Eur J Cancer. 2014 Mar.

. 2014 Mar;50(5):1042-3.

doi: 10.1016/j.ejca.2013.12.016. Epub 2014 Jan 13.

¹ The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, United Kingdom.
² Guy's and St. Thomas NHS Foundation Trust, United Kingdom.
³ The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, United Kingdom. Electronic address: Johann.De-Bono@icr.ac.uk.

No abstract available

Comment on

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS. Bianchini D, et al. Eur J Cancer. 2014 Jan;50(1):78-84. doi: 10.1016/j.ejca.2013.08.020. Epub 2013 Sep 25. Eur J Cancer. 2014. PMID: 24074764
Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer.
Thomson D, Charnley N, Parikh O. Thomson D, et al. Eur J Cancer. 2014 Mar;50(5):1040-1. doi: 10.1016/j.ejca.2013.12.017. Epub 2014 Jan 22. Eur J Cancer. 2014. PMID: 24462374 No abstract available.